Results 61 to 70 of about 2,108 (191)

Real world outcomes of faricimab in treatment resistant neovascular age-related macular degeneration among Asian patients

Scientific Reports
To describe the real-world efficacy and safety outcome measurements of faricimab use in treatment-resistant neovascular age-related macular degeneration (nAMD) in a cohort of Asian patients.
Elvine Zhong Oen Neo, Kevin Wei Onn Liang, Zhi Hong Toh, Andrew Bee Yong Tan, Darren Mun Yoong Choy, Wenting Zhou, Helen Fang Mi, Louis Wei Yi Lim, Yu Qiang Soh, Jacob Yu Hang Chin, Zheng Xian Thng, Karen Jhi Wen Chia, Augustinus Laude, Colin Siang Hui Tan, Tock Han Lim, Nicola Yi’an Gan, Rajesh Rajagopalan, Wei Kiong Ngo   +17 more
doaj   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, EarlyView.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Pigment Epithelium‐Derived Factor (PEDF)‐Based Therapy Induced Photoreceptor Survival by Stabilizing Choroidal Neovessels in a VEGF Overexpression CNV Rat Model

The FASEB Journal, Volume 39, Issue 19, 15 October 2025.
Stabilizing choroidal neovessels offers a novel treatment‐option for pathological CNV. Pigment epithelium‐derived factor (PEDF), a multifunctional protein with vessel‐stabilizing properties, is a promising candidate for this approach. Its efficacy with and without bevacizumab was tested in a VEGF overexpression CNV rat model.
Alexander V. Tschulakow, Lei Xi, Ulrich Schraermeyer, Sylvie Julien   +3 more
wiley   +1 more source

Changes in Macular Pigment Optical Density after Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration: A Pilot Study [PDF]

: Background: This study aimed to evaluate the effects of faricimab intravitreal injections in patients with exudative age macular degeneration (nAMD) after the loading dose using spectral domain optical coherence tomography (SD-OCT) and macular pigment ...
Cennamo, Gilda, Chiosi, Flavia, Costagliola, Ciro, Rinaldi, Michele   +3 more
core   +1 more source

Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis

Ophthalmology and Therapy
This is a summary of the original article ‟Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis”. DMO, a serious eye condition that can lead to vision loss in people with diabetes, is a significant health ...
Christian Bührer, Thomas Paling, Richard Gale, Tatiana Paulo, Marloes Bagijn   +4 more
doaj   +1 more source

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

Advanced Science, Volume 12, Issue 39, October 20, 2025.
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz, Jessica Cutrufello, Michael Lam, Shreya Nallaparaju, Nicholas A. Peppas   +4 more
wiley   +1 more source

Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema [PDF]

Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking.
Akil, Handan, Borchert, Grace A., Cehajic-Kapetanovic, Jasmina, Charbel Issa, Peter, De Silva, Samantha R., Downes, Susan M., Fischer, M. Dominik, Gkika, Theodora, Kiire, Christine A., MacLaren, Robert E., Stone, Niamh M., Xue, Kanmin   +11 more
core   +2 more sources

Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion. 72-Week Results from the BALATON and COMINO Trials [PDF]

To assess the efficacy, durability, and safety of dual angiopoietin-2/VEGF inhibition with faricimab dosed per a modified treat-and-extend-based regimen in patients with retinal vein occlusion.Single-arm treatment period after a randomized, double-masked,
Abreu Francis, Arrisi Pablo, Danzig Carl J, Dinah Christiana, Ghanchi Faruque, Hattenbach Lars-Olof, Khanani Arshad M, Lai Timothy Y Y, Liu Ying, Paris Liliana P, Retiere Anne-Cecile, Schlottmann Patricio G, Shimura Masahiko, Tóth-Molnár Edit, Willis Jeffrey R   +14 more
core   +1 more source

Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Ophthalmology and Therapy
Introduction The aim of this study was to compare the estimated direct and indirect costs with aflibercept 8 mg and faricimab in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) over 5 years.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh Patel   +5 more
doaj   +1 more source

Comparative efficacy and safety of Faricimab with other intravitreal anti-vascular endothelial growth factor in the treatment of Neovascular age related macular degeneration- A Systematic review and meta-analysis

Asian Journal of Medical Sciences
Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients age 50 and older, with an estimated 200 million people affected worldwide.
Renuga Devi Kaliaperumal , Nandhini P, Reena Mohan , Nallamuthu P , Jenifer Florence Mary J   +4 more
doaj   +1 more source